Treatments for specific symptoms and populations

This category includes treatments for specific symptoms of, and populations with, bipolar disorder. This includes people with suicidal behaviours, those with substance use problems, and for children and pregnant women.

Treatments during pregnancy and breastfeeding

How is medication during pregnancy and breastfeeding important? Medication use during pregnancy requires careful consideration of the mother’s risk of illness relapse against the risk of harm or complications for the developing infant if medication is to be continued. However, there is currently very little robust evidence regarding the use of medications for bipolar disorder during pregnancy and the postpartum period. What is the evidence for medication use during pregnancy and breastfeeding? Moderate to low quality evidence suggests a small increased risk of heart defect or lower birth weight in infants exposed to antipsychotics in utero, and a small increased…

Treatments for aggression and agitation

How are treatments for aggression and agitation relevant to bipolar disorder? Agitation and/or aggression are sometimes observed during a psychiatric emergency such as in onset of acute psychosis. Agitation typically includes irritability and restlessness, motor or verbal hyperactivity, uncooperativeness, and occasionally aggressive gestures or behaviour. This can pose a risk both to the individual, as well as the attending health care professionals, and so is important to manage this behaviour and prevent potential harm. What is the evidence for treatments for aggression and agitation? Moderate to low quality evidence suggests intramuscular olanzapine (10mg x 2 doses + 5mg x 1…

Treatments for bipolar II disorder

What is bipolar II disorder? Bipolar II disorder is a common, recurrent, and disabling psychiatric illness. The lifetime incidence ranges from 1% to 11% depending on the method of diagnosis. DSM-IV defines bipolar II disorder as a lifetime history of at least one episode of major depression plus at least one episode of hypomania. By definition, individuals with bipolar II disorder never experience full-blown mania, unlike those with a diagnosis of bipolar I disorder. Bipolar II disorder is characterised by multiple and often protracted depressive episodes, and a lower probability of returning to premorbid levels of functioning between episodes. What…

Treatments for bipolar versus unipolar depression

How are bipolar and unipolar depression different? Bipolar disorders are a group of disorders characterised by episodes of depression and mania or hypomania. Bipolar disorders described in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, version 5) include bipolar I disorder involving severe depression and mania, bipolar II disorder involving depression and hypomania (less severe mania), and cyclothymic disorder involving many mood swings, with hypomania and depressive symptoms occurring often and fairly constantly. Major depressive disorder characterised in the DSM-5 involves five (or more) of the following symptoms to be present and represent a change from previous functioning. At…

Treatments for children

What is childhood bipolar disorder? Bipolar disorder is a chronic psychiatric illness that can have devastating effects on individuals and their families. It is the sixth leading cause of disability worldwide, with prevalence estimated to be around 1% in the general adult population. The age of onset of bipolar disorder typically occurs during early adulthood, although onset can occur in childhood or adolescence. Bipolar disorder in childhood and adolescence is commonly associated with impairment in multiple domains, including increased risk of psychiatric hospitalisation, antisocial behaviour, addictions, and suicidal behaviour. There is a need to optimise treatments for childhood patients for…

Treatments for cognitive symptoms

What are cognitive symptoms of bipolar disorder? Cognitive symptoms in people with bipolar disorder may be apparent in many cognitive domains, including executive function, memory, and attention, and may develop prior to the core mood symptoms of bipolar. Cognitive symptoms are highly disabling and may predict poor functional outcomes What is the evidence for pharmaceutical treatments for cognitive symptoms? Low quality evidence is unclear of the benefits of pharmaceutical treatments for cognition in people with bipolar disorder. April 2019

Treatments for dual diagnosis

What is dual diagnosis? Several treatments have been targeted to people with ‘dual diagnosis’; both a psychiatric disorder and a substance use disorder. Studies of dual diagnosis may investigate the availability and effectiveness of treatments for either diagnosis, including symptom severity, substance use, social functioning, quality of life, and also, cognition. What is the evidence for treatments for dual diagnosis? Low quality evidence is unclear as to any benefit of pharmaceutical treatments for dual diagnosis. Review authors conclude that the valproate and naltrexone may be effective for reducing excessive alcohol consumption. Citicoline may decrease cocaine use and enhance declarative memory….

Treatments for elderly patients

Why study bipolar disorder in older patients? Elderly people with bipolar disorder are a heterogeneous group of patients who tend to have comorbidities and poor outcomes. They constitute between 5% and 20% of patients presenting for acute treatment at geriatric psychiatry services. Although the psychopathologic manifestations of mania are similar in older and younger patients, response to treatment can be extremely variable. What is the evidence for pharmaceutical treatments for older people with bipolar disorder? Moderate to low quality evidence suggests lithium may be effective and well-tolerated in older patients with bipolar disorder. April 2019

Treatments for first-episode bipolar disorder

We have not found any systematic reviews on this topic that meet the inclusion criteria. Pending enough primary studies, we invite reviews on this topic to be conducted. Alternatively we will endeavour to conduct our own review to fill this gap in the Library. April 2019

Treatments for high-risk groups

We have not found any systematic reviews on this topic that meet the inclusion criteria. Pending enough primary studies, we invite reviews on this topic to be conducted. Alternatively we will endeavour to conduct our own review to fill this gap in the Library. April 2019

Treatments for medication resistance

What is medication resistance? Bipolar disorder is a persistent, episodic and debilitating condition associated with recurring episodes of mania, hypomania, depression, and mixed manic-depressive states. These symptoms can lead to severe functional impairment, substance abuse, and suicidal behaviour. Treatment guidelines advocate the use of individual medications, with multiple medications indicated when a patient relapses on maintenance treatment. Unsatisfactory response to therapies is common in bipolar disorder, particularly during depression episodes. Hence, there is a need to study medications that specifically target people with treatment resistance. What is the evidence for medication-resistance? Moderate to low quality evidence suggests clozapine and triiodothyronine…

Treatments for mixed states

What are mixed states in bipolar disorder? Bipolar disorders are a group of disorders characterised by episodes of mania or hypomania and depression. Concurrent ‘mixed’ episodes of both mania and depression can also be present. For a mixed episode, the latest Diagnostic and Statistical Manual of Mental Disorders (DSM-5) states a requirement of at least three manic/hypomanic symptoms (e.g. elevated mood, inflated self-esteem, decreased sleep, increased energy) occurring nearly every day during a major depressive episode. Alternatively, the presence of at least three symptoms of depression (e.g. depressed mood, diminished interest or pleasure, slowed physical and emotional reaction, fatigue or…

Treatments for rapid cycling

What is rapid cycling in bipolar disorder? Rapid cycling refers to the presence of four or more discrete mood episodes (mania, hypomania, depression, or mixed) during a one-year period. Studies have suggested that rapid mood cycling is more frequent in women than in men, and has been associated with hypothyroidism and bipolar II disorder (hypomania rather than mania). It is also associated with longer illness duration, greater illness severity, and worse global functioning. What is the evidence for pharmaceutical treatments for rapid cycling? Moderate to low quality evidence suggests the antipsychotics olanzapine, quetiapine, and aripiprazole, and the anticonvulsants divalproex and…

Treatments for relapse prevention

How are medications related to relapse? Bipolar disorder is a disabling condition characterised by episodes of mania or hypomania and depression. Adherence to pharmacological treatment is critical for effective control of symptoms and to prevent relapse. What is the evidence for pharmaceutical treatments for relapse prevention? Medications compared to placebo Moderate to high quality evidence suggests fewer relapses to mania with risperidone, olanzapine, and quetiapine. Lower quality evidence suggests fewer relapses to mania with aripiprazole. There were fewer relapses to depression with olanzapine and quetiapine, but not with risperidone or aripiprazole. Moderate quality evidence suggests fewer relapses in general with…

Treatments for suicide and self-harm

How are suicide and self-harm relevant to people with bipolar disorder? Rates of suicide or self-harm are considerably higher in people with mental disorders compared to people without a mental disorder. There has been much research dedicated to determining potential risk factors for suicide, which may have clinically important applications for prevention. Many of the important risk factors for suicide in the general population can apply to people with mental disorders, including having depression and/or a history of previous suicide attempts. What is the evidence for treatments for suicide and self-harm? Moderate to high quality evidence suggests self-harm, but not…

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.